{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:52:52Z","timestamp":1794847972130,"version":"4.9.1"},"reference-count":60,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"unspecified","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"University of Lancashire","award":["UURIP internship 2025 for the University of Lancas"],"award-info":[{"award-number":["UURIP internship 2025 for the University of Lancas"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To systematically synthesise available evidence on the safety of advanced combination therapy (ACT) in adults with inflammatory bowel disease (IBD), with secondary exploratory evaluation of efficacy outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Searches of Embase (via Ovid), MEDLINE and PubMed were initially undertaken on 9 May 2025 and updated on 8 April 2026. Additional studies were identified through hand-searching and reference list screening. Eligible publications were restricted to those published between 1 January 2015 and 31 March 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>We included randomised controlled trials as well as observational and descriptive studies. Conference abstracts, reviews, editorials and commentaries were excluded. Inclusion was restricted to publications in English.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Two reviewers independently screened studies, extracted data and assessed risk of bias using Joanna Briggs Institute tools and Cochrane RoB-1. Pooled proportions of total adverse events (TAEs), serious adverse events (SAEs) and treatment discontinuations were calculated using random-effects meta-analysis. Subgroup analyses were conducted by drug class. Where meta-analysis was not appropriate, findings were narratively synthesised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-two studies (n=2022 participants) were included. The most frequent combinations were anti-TNFa plus integrin inhibitors and interleukin (IL) 23 plus integrin inhibitors. Pooled analyses demonstrated low rates of SAEs (eg, anti-TNFa plus integrin inhibitors: 2.7%, 95% CI 0.22% to 6.86%) and discontinuations (6.38%, 95% CI 2.36% to 11.58%), although heterogeneity was substantial and certainty of evidence was very low, with some analyses based on small sample sizes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ACT may be associated with low rates of SAEs in selected patients with refractory IBD; however, the evidence is limited by small sample sizes, heterogeneity and predominantly observational designs. Robust conclusions regarding safety and efficacy cannot be made due to very low GRADE certainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD420251025883<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2026-002307","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:35:18Z","timestamp":1781195718000},"page":"e002307","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-0810","authenticated-orcid":false,"given":"Shellie","family":"Radford","sequence":"first","affiliation":[{"name":"The University of Nottingham School of Medicine, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Arruda Navarro","family":"Albuquerque","sequence":"additional","affiliation":[{"name":"Biomedical Evidence Synthesis and Translation to practice (BEST), University of Lancashire, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zara","family":"Najeeb","sequence":"additional","affiliation":[{"name":"The University of Nottingham School of Medicine, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debangsh","family":"Agarwal","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Lancashire, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-6658","authenticated-orcid":false,"given":"Anoop","family":"John","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Gordon","sequence":"additional","affiliation":[{"name":"Biomedical Evidence Synthesis and Translation to practice (BEST), University of Lancashire, Preston, UK"},{"name":"Department of Child Health, Blackpool Teaching Hospital NHS, Blackpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Sinopoulou","sequence":"additional","affiliation":[{"name":"Biomedical Evidence Synthesis and Translation to practice (BEST), University of Lancashire, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8906-6908","authenticated-orcid":false,"given":"Gordon","family":"Moran","sequence":"additional","affiliation":[{"name":"The University of Nottingham School of Medicine, Nottingham, UK"},{"name":"Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"2026061109351054000_13.1.e002307.1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae091"},{"key":"2026061109351054000_13.1.e002307.2","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJAB178"},{"key":"2026061109351054000_13.1.e002307.3","first-page":"1","article-title":"BSG 2024 IBD guidelines protocol (standard operating procedures)","volume":"10","author":"Darie","year":"2023","journal-title":"BMJ Open Gastroenterol"},{"key":"2026061109351054000_13.1.e002307.4","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.0886","article-title":"P756 Efficacy and safety of medical therapies for maintenance of surgically induced remission in Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"18","author":"Sinopoulou","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026061109351054000_13.1.e002307.5","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.1173","article-title":"P1043 Immunomodulator and advanced therapies for prevention of clinical relapse and loss of response during maintenance phase in Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"18","author":"Sinopoulou","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026061109351054000_13.1.e002307.6","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.0686","article-title":"P556 Immunomodulator and advanced therapies for Induction of clinical remission and response in Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"18","author":"Sinopoulou","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026061109351054000_13.1.e002307.7","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.1173","article-title":"P1043 Immunomodulator and advanced therapies for prevention of clinical relapse and loss of response during maintenance phase in Crohn\u2019s disease: a systematic review and network meta-analysis","volume":"18","author":"Sinopoulou","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026061109351054000_13.1.e002307.8","first-page":"360","article-title":"Approach to treatment failure in inflammatory bowel disease","volume":"18","author":"Moss","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2026061109351054000_13.1.e002307.9","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000440983.86659.81"},{"key":"2026061109351054000_13.1.e002307.10","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw144"},{"key":"2026061109351054000_13.1.e002307.11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-334395"},{"key":"2026061109351054000_13.1.e002307.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-105790","article-title":"Identification of novel molecular drivers, prognostic and diagnostic biomarkers for Inflammatory Bowel Disease (IBD): protocol for the Nottingham\/AstraZeneca prospective IBD observational cohort study","volume":"15","author":"Serna-Valverde","year":"2025","journal-title":"BMJ Open"},{"key":"2026061109351054000_13.1.e002307.13","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061109351054000_13.1.e002307.14","doi-asserted-by":"crossref","DOI":"10.3390\/biom15020222","article-title":"Dual therapy in inflammatory bowel disease","volume":"15","author":"Altieri","year":"2025","journal-title":"Biomolecules"},{"key":"2026061109351054000_13.1.e002307.15","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1007\/s10620-023-07837-0","article-title":"Efficacy and safety of dual targeted therapy for partially or non-responsive inflammatory bowel disease: a systematic review of the literature","volume":"68","author":"Berinstein","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2026061109351054000_13.1.e002307.16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061109351054000_13.1.e002307.17","doi-asserted-by":"crossref","unstructured":"Gros B , Varkas G , Speeckaert R , et al . Combining advanced therapies in patients with inflammatory bowel disease and extraintestinal manifestations or associated immune-mediated diseases: who, what, when and at what cost? Frontline Gastroenterol 2025. doi:10.1136\/flgastro-2024-102967","DOI":"10.1136\/flgastro-2024-102967"},{"key":"2026061109351054000_13.1.e002307.18","doi-asserted-by":"crossref","DOI":"10.1093\/crocol\/otac002","article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"2026061109351054000_13.1.e002307.19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/00365521.2019.1597159","article-title":"Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis","volume":"54","author":"Ribaldone","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"2026061109351054000_13.1.e002307.20","doi-asserted-by":"crossref","unstructured":"Fabisiak A , Caban M , Dudek P , et al . Advancements in dual biologic therapy for inflammatory bowel diseases: efficacy, safety, and future directions. Therap Adv Gastroenterol 2025;18. doi:10.1177\/17562848241309871","DOI":"10.1177\/17562848241309871"},{"key":"2026061109351054000_13.1.e002307.21","first-page":"406","article-title":"Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature","volume":"17","author":"Gold","year":"2021","journal-title":"Gastroenterol Hepatol (Que)"},{"key":"2026061109351054000_13.1.e002307.22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/ibd\/izaf188","article-title":"Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel diseases","volume":"32","author":"Anderson","year":"2026","journal-title":"Inflamm Bowel Dis"},{"key":"2026061109351054000_13.1.e002307.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026061109351054000_13.1.e002307.24","unstructured":"M. Z. Moola S , Tufanaru C , Aromataris E , et al . JBI manual for evidence synthesis. JBI, 2020."},{"key":"2026061109351054000_13.1.e002307.25","unstructured":"T. J. Higgins JPT , Chandler J , Cumpston M , et al . Cochrane handbook for systematic reviews of interventions.2024. Available: www.cochrane.org\/handbook"},{"key":"2026061109351054000_13.1.e002307.26","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1093\/ibd\/izaf085","article-title":"Developing IBD outcome effect size thresholds to inform research, guidelines, and clinical decisions","volume":"31","author":"Gordon","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026061109351054000_13.1.e002307.27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ajd.14185","article-title":"Combination treatment with monoclonal antibodies: dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease","volume":"65","author":"Alegre-Bailo","year":"2024","journal-title":"Australas J Dermatol"},{"key":"2026061109351054000_13.1.e002307.28","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.12998\/wjcc.v10.i8.2569","article-title":"Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn\u2019s disease: a case report and review of literature","volume":"10","author":"Au","year":"2022","journal-title":"World J Clin Cases"},{"key":"2026061109351054000_13.1.e002307.29","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/apt.14567","article-title":"Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti\u2010tumour necrosis factor","volume":"47","author":"Ben\u2010Horin","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061109351054000_13.1.e002307.30","doi-asserted-by":"crossref","unstructured":"Bianchi E , Pata AP , Cantarini L , et al . Upadacitinib and ustekinumab combination treatment for a refractory case of spondyloarthritis and Crohn\u2019s disease. Clin Exp Rheumatol 2023;0766. doi:10.55563\/clinexprheumatol\/qsy3kc","DOI":"10.55563\/clinexprheumatol\/qsy3kc"},{"key":"2026061109351054000_13.1.e002307.31","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/MEG.0000000000001919","article-title":"Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab","volume":"32","author":"Biscaglia","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026061109351054000_13.1.e002307.32","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002437"},{"key":"2026061109351054000_13.1.e002307.33","doi-asserted-by":"crossref","unstructured":"Buend\u00eda Carcedo L , Arreba Gonz\u00e1lez P , Higuera \u00c1lvarez R , et al . Combination treatment risankizumab and subcutaneous infliximab for refractory Crohn\u2019s disease: a case report. Rev Esp Enferm Dig 2024;187\u20138. doi:10.17235\/reed.2024.10919\/2024","DOI":"10.17235\/reed.2024.10919\/2024"},{"key":"2026061109351054000_13.1.e002307.34","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/ibd\/izx110","article-title":"Combining anti-TNF-\u03b1 and vedolizumab in the treatment of inflammatory bowel disease: a case series","volume":"24","author":"Buer","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026061109351054000_13.1.e002307.35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5070\/D3259045519","article-title":"Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab","volume":"25","author":"Cline","year":"2019","journal-title":"Dermatol Online J"},{"key":"2026061109351054000_13.1.e002307.36","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn\u2019s disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061109351054000_13.1.e002307.37","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1093\/ibd\/izaa092","article-title":"Double biologic therapy for refractory stricturing Crohn\u2019s disease: a successful case of deep remission with ustekinumab and vedolizumab","volume":"26","author":"Elmoursi","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026061109351054000_13.1.e002307.38","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/00365521.2022.2045350","article-title":"Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study","volume":"57","author":"Eronen","year":"2022","journal-title":"Scand J Gastroenterol"},{"key":"2026061109351054000_13.1.e002307.39","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061109351054000_13.1.e002307.40","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.12998\/wjcc.v12.i23.5441","article-title":"Rare extraintestinal manifestations of ulcerative colitis treated with dual biologic therapy: a case report","volume":"12","author":"Filipiuk","year":"2024","journal-title":"World J Clin Cases"},{"key":"2026061109351054000_13.1.e002307.41","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ueg2.12170","article-title":"Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: a European retrospective observational study","volume":"9","author":"Goessens","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"2026061109351054000_13.1.e002307.42","doi-asserted-by":"crossref","DOI":"10.1093\/crocol\/otae080","article-title":"Dual biologic therapy induces remission in refractory Crohn\u2019s disease with vedolizumab and ustekinumab","volume":"7","author":"Hassan","year":"2024","journal-title":"Crohn\u2019s & Colitis 360"},{"key":"2026061109351054000_13.1.e002307.43","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241307598","article-title":"Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China","volume":"18","author":"Jin","year":"2025","journal-title":"Therap Adv Gastroenterol"},{"key":"2026061109351054000_13.1.e002307.44","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cgh.2018.08.017","article-title":"Combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and spondyloarthropathy","volume":"17","author":"Le Berre","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061109351054000_13.1.e002307.45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000542759","article-title":"Risankizumab and certolizumab pegol dual-targeted therapy for Crohn\u2019s disease and axial spondyloarthritis: a case report","volume":"19","author":"Lehmann","year":"2024","journal-title":"Case Rep Gastroenterol"},{"key":"2026061109351054000_13.1.e002307.46","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/imj.16120","article-title":"Combination non tumour necrosis factor biologic and small-molecule therapy in a patient with ankylosing spondylitis and Crohn disease","volume":"53","author":"Li","year":"2023","journal-title":"Intern Med J"},{"key":"2026061109351054000_13.1.e002307.47","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5264216","article-title":"Ustekinumab and vedolizumab dual biologic therapy in the treatment of Crohn\u2019s disease","volume":"2017","author":"Liu","year":"2017","journal-title":"Case Rep Med"},{"key":"2026061109351054000_13.1.e002307.48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2018-000243","article-title":"Safety of dual biological therapy in Crohn\u2019s disease: a case series of vedolizumab in combination with other biologics","volume":"5","author":"Mao","year":"2018","journal-title":"BMJ Open Gastroenterol"},{"key":"2026061109351054000_13.1.e002307.49","doi-asserted-by":"crossref","unstructured":"Mart\u00ed Romero L , Pe\u00f1o Mu\u00f1oz L , Mart\u00ednez Escapa V , et al . Use of teduglutide for short bowel syndrome and Crohn\u2019s disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy. Rev Esp Enferm Dig 2022;331\u20132. doi:10.17235\/reed.2022.9194\/2022","DOI":"10.17235\/reed.2022.9194\/2022"},{"key":"2026061109351054000_13.1.e002307.50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10620-023-08182-y","article-title":"Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn\u2019s disease","volume":"69","author":"Miyatani","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2026061109351054000_13.1.e002307.51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/apt.70309","article-title":"Efficacy and safety of vedolizumab and tofacitinib (VETO) combination therapy in refractory ulcerative colitis unresponsive to anti-TNF and a second-line advanced therapy: a prospective cohort nested within a randomised trial","volume":"63","author":"Neelam","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061109351054000_13.1.e002307.52","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/ecco-jcc\/jjaa149","article-title":"Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease","volume":"15","author":"Privitera","year":"2021","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026061109351054000_13.1.e002307.53","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20014"},{"key":"2026061109351054000_13.1.e002307.54","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.14309\/01.ajg.0000705628.04061.db","article-title":"S0895 Is two better than one? Combination therapy with vedolizumab and tofacitinib for the treatment of patients with inflammatory bowel disease","volume":"115","author":"Scheinberg","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2026061109351054000_13.1.e002307.55","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/apt.15719","article-title":"Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn\u2019s disease","volume":"51","author":"Yang","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061109351054000_13.1.e002307.56","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/ibd\/izae105","article-title":"Short-term use of upadacitinib in combination with biologic therapy for inducing clinical remission in patients with active inflammatory bowel disease","volume":"30","author":"Yin","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026061109351054000_13.1.e002307.57","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/ajg.2016.66","article-title":"Ustekinumab and anti-TNF combination therapy in patients with inflammatory bowel disease","volume":"111","author":"Yzet","year":"2016","journal-title":"American Journal of Gastroenterology"},{"key":"2026061109351054000_13.1.e002307.58","doi-asserted-by":"crossref","first-page":"i197","DOI":"10.1093\/ecco-jcc\/jjae190.0097","article-title":"DOP058 efficacy and safety of vedolizumab combined with upadacitinib in moderate-to-severe ulcerative colitis: a multicenter, prospective, randomized controlled trial","volume":"19","author":"Wu","year":"2025","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026061109351054000_13.1.e002307.59","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103582","article-title":"An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease","volume":"89","author":"Solitano","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026061109351054000_13.1.e002307.60","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.3748\/wjg.v27.i43.7572","article-title":"Minimum sample size estimates for trials in inflammatory bowel disease: a systematic review of a support resource","volume":"27","author":"Gordon","year":"2021","journal-title":"World J Gastroenterol"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2026-002307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:35:25Z","timestamp":1781195725000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2026-002307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6,11]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/bmjgast-2026-002307"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2026-002307","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}